Cipher's revised NDA for CIP-TRAMADOL ER accepted for rev... (is listed on the Toronto Stock Exchange ...)

Cipher's revised NDA for CIP-TRAMADOL ER accepted for review by FDA

Date:6/17/2008

is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit http://www.cipherpharma.com.

Forward-Looking Statements

Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. Some forward-looking statements may be identified by words like "may", "will", "anticipate", "estimate", "expect", "intend", or "continue" or the negative thereof or similar variations. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities, such as the applicability of patents and proprietary technology; possible patent litigation; regulatory approval of products in the Company's pipeline; changes in government regulation or regulatory approval processes; government and third-party payer reimbursement; dependence on strategic partnerships for product candidates and technologies, marketing and R&D services; meeting projected drug development timelines and goals; intensifying competition; rapid technological change in the pharmaceutical industry; anticipated future losses; the ability to access capital to fund R&D; and the ability to attract and retain key personnel. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn
2. Chest Compressions Key to Revised CPR Guidelines
3. Schedules Revised for Flu, Meningitis Vaccines
4. Mayo researchers say ECG standards should be revised for elderly
5. Mayo Researchers Say ECG Standards Should Be Revised for Elderly
6. USP announces revised glycerin monograph
7. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
8. Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain
9. Revised: Morris Animal Foundation Searches for Americas Best Vet With Thank Your Vet for a Healthy Pet(SM) Contest
10. Cipher Appeals FDAs Decision On CIP-TRAMADOL ER
11. Cipher provides CIP-TRAMADOL ER regulatory update

Post Your Comments:

Cipher's revised NDA for CIP-TRAMADOL ER accepted for rev...(is listed on the Toronto Stock Exchange ...),Health